This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yasui, W. Articles by Tahara, E. Search for Related Content PubMed PubMed Citation Articles by Yasui, W. Articles by Tahara, E.

Expression of Epidermal Growth Factor Receptor in Human Gastric and Colonic Carcinomas¹

First Department of Pathology, Hiroshima University School of Medicine, 1-2-3 Kasumi, Minami-ku, Hiroshima 734, Japan

The expression of epidermal growth factor (EGF) receptor was examined immunohistochemically in a total of 122 gastric and 61 colonic carcinomas, out of which 16 gastric and 8 colonic carcinomas were also examined by ¹²⁵I-labeled EGF binding analysis and Western blotting. The values of EGF binding were 12.68 ± 1.98 (SE; n = 16) fmol/mg protein in gastric carcinomas and 5.72 ± 2.15 (n = 8) fmol/mg protein in nonneoplastic gastric mucosa, the difference being significant (P < 0.01). In the colonic tissue, the binding capacities in carcinomas and nonneoplastic mucosa were 13.29 ± 4.17 (n = 8) and 10.68 ± 0.41 (n = 3) fmol/mg protein, respectively. Scatchard analysis of ¹²⁵I-labeled EGF binding indicated a single class of receptors in gastric and colonic carcinomas with an apparent K_d value of from 111 to 277 (n = 4) and from 87.4 to 341 fM (n = 5), respectively, except for one gastric carcinoma having two classes of receptors (K_d = 15.9 and 896 fM). In Western blotting using monoclonal anti-EGF receptor antibody, various levels of EGF receptor expression were detected in 12 (85.7%) of the 14 gastric carcinomas and in 7 (87.5%) of the 8 colonic carcinomas. Immunohistochemically, EGF receptor immunoreactivity was detected in one (3.8%) of the 26 early gastric carcinomas, while it was observed in 33 (34.4%) of the 96 advanced gastric carcinomas, the incidence between the two being significantly different (P < 0.01). In the colonic carcinomas, 47 (77.1%) of the 61 cases showed positive immunoreactivity to EGF receptor, which did not differ by histological type.

¹ Supported in part by a Grant-in-Aid for Cancer Research from the Ministry of Health and Welfare for a Comprehensive 10-Year Strategy for Cancer Control, Japan.

² To whom requests for reprints should be addressed.

Received 3/16/87. Revised 9/ 4/87. Accepted 9/30/87.

This article has been cited by other articles:

				M. P. Melancon, W. Lu, Z. Yang, R. Zhang, Z. Cheng, A. M. Elliot, J. Stafford, T. Olson, J. Z. Zhang, and C. Li In vitro and in vivo targeting of hollow gold nanoshells directed at epidermal growth factor receptor for photothermal ablation therapy Mol. Cancer Ther., June 1, 2008; 7(6): 1730 - 1739. [Abstract] [Full Text] [PDF]

				A. Fichera, N. Little, S. Jagadeeswaran, U. Dougherty, A. Sehdev, R. Mustafi, S. Cerda, W. Yuan, S. Khare, M. Tretiakova, et al. Epidermal Growth Factor Receptor Signaling Is Required for Microadenoma Formation in the Mouse Azoxymethane Model of Colonic Carcinogenesis Cancer Res., January 15, 2007; 67(2): 827 - 835. [Abstract] [Full Text] [PDF]

				M. Kimura, H. Tsuda, D. Morita, E. Shinto, T. Tanimoto, T. Ichikura, H. Mochizuki, and O. Matsubara Usefulness and Limitation of Multiple Endoscopic Biopsy Sampling for Epidermal Growth Factor Receptor and c-erbB-2 Testing in Patients with Gastric Adenocarcinoma Jpn. J. Clin. Oncol., June 1, 2005; 35(6): 324 - 331. [Abstract] [Full Text] [PDF]

				J. P. Spano, R. Fagard, J.-C. Soria, O. Rixe, D. Khayat, and G. Milano Epidermal growth factor receptor signaling in colorectal cancer: preclinical data and therapeutic perspectives Ann. Onc., February 1, 2005; 16(2): 189 - 194. [Abstract] [Full Text] [PDF]

				J.-P. Spano, C. Lagorce, D. Atlan, G. Milano, J. Domont, R. Benamouzig, A. Attar, J. Benichou, A. Martin, J.-F. Morere, et al. Impact of EGFR expression on colorectal cancer patient prognosis and survival Ann. Onc., January 1, 2005; 16(1): 102 - 108. [Abstract] [Full Text] [PDF]

				J. E. Thompson and C. B. Thompson Putting the Rap on Akt J. Clin. Oncol., October 15, 2004; 22(20): 4217 - 4226. [Abstract] [Full Text] [PDF]

				A. A. Parikh, F. Fan, W. B. Liu, S. A. Ahmad, O. Stoeltzing, N. Reinmuth, D. Bielenberg, C. D. Bucana, M. Klagsbrun, and L. M. Ellis Neuropilin-1 in Human Colon Cancer: Expression, Regulation, and Role in Induction of Angiogenesis Am. J. Pathol., June 1, 2004; 164(6): 2139 - 2151. [Abstract] [Full Text] [PDF]

				S. Ke, X. Wen, M. Gurfinkel, C. Charnsangavej, S. Wallace, E. M. Sevick-Muraca, and C. Li Near-Infrared Optical Imaging of Epidermal Growth Factor Receptor in Breast Cancer Xenografts Cancer Res., November 15, 2003; 63(22): 7870 - 7875. [Abstract] [Full Text] [PDF]

				I. Garcia, F. Vizoso, A. Martin, L. Sanz, O. Abdel-Lah, P. Raigoso, and J.L. Garcia-Muniz Clinical Significance of the Epidermal Growth Factor Receptor and HER2 Receptor in Resectable Gastric Cancer Ann. Surg. Oncol., April 1, 2003; 10(3): 234 - 241. [Abstract] [Full Text] [PDF]

				X. Wen, Q.-P. Wu, S. Ke, L. Ellis, C. Charnsangavej, A. S. Delpassand, S. Wallace, and C. Li Conjugation with 111In-DTPA-Poly(Ethylene Glycol) Improves Imaging of Anti-EGF Receptor Antibody C225 J. Nucl. Med., October 1, 2001; 42(10): 1530 - 1537. [Abstract] [Full Text] [PDF]